Fennec Pharmaceuticals Inc
F:RV41
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
F
|
Fennec Pharmaceuticals Inc
F:RV41
|
US |
|
B
|
Bell Copper Corp
OTC:BCUFF
|
CA |
|
Granges AB
F:9GR
|
SE |
|
A
|
Autodesk Inc
F:AUD
|
US |
|
Healios KK
F:6VX
|
JP |
|
M
|
Marsh & McLennan Companies Inc
XMUN:MSN
|
US |
|
S
|
Surteco Group SE
XMUN:SUR
|
DE |
|
C
|
Carlisle Companies Inc
DUS:CLE
|
US |
|
COPT Defense Properties
NYSE:CDP
|
US |
|
M
|
Marsh & McLennan Companies Inc
F:MSN
|
US |
|
C
|
Carlisle Companies Inc
XMUN:CLE
|
US |
|
M
|
Merck KGaA
XMUN:MRK
|
DE |
Intrinsic Value
Is RV41 undervalued or overvalued?
See the intrinsic value estimate for Fennec Pharmaceuticals Inc and find out whether today’s valuation is cheap or expensive by its own historical standards.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Fennec Pharmaceuticals Does
Fennec Pharmaceuticals is a small specialty drug company focused on one main problem in cancer care: protecting children from hearing loss caused by the chemotherapy drug cisplatin. Its lead product, PEDMARK, is a prescription treatment used alongside cisplatin for patients with certain solid tumors. The company’s business is built around developing and commercializing this medicine for hospitals, cancer centers, and pediatric oncologists that treat these patients.
- Headquarters
- United States of America US
- Employees
- 35
- IPO date
- Jun 5, 2001
Revenue & Expenses Breakdown
Fennec Pharmaceuticals Inc
Earnings Waterfall
Fennec Pharmaceuticals Inc
The intrinsic value for Fennec Pharmaceuticals Inc (RV41) under the Base Case is hidden EUR.
Compared with the current market price of 8.75 EUR, the stock appears hidden.